Louis Navellier

We call it the zigzag theory. You want to find something that zigs and something that zags and blend them together to get a better combined performance.

One of the things that launched the strength in biotech is when the pharmaceutical industry itself got a little slow.

If you go back to 2001, the market had two violent short covering rallies then, although I know the market didn't officially get going until March 2003.

As a rule, bond funds will not double your money overnight.

Large-caps were safe in 1996, '97, '98. Everybody was buying index funds and Nifty Fifty funds. As long as money was pouring in, it was great.

Internally, when we manage portfolios, we figure out what works in large cap, what works in mid cap, what works in small cap. Generally speaking, large cap stocks want earning stability, strong cash flow, margin expansion.

There are several things that can create an alpha - stock buybacks are one. High dividend yields are another, especially nowadays because the stock market yields more than the banks and the tenure treasury. But by and large, it tends to be companies with a strong cash flow, rising sales, accelerated earnings, a profit margin expansion.

What we do is we test what works on Wall Street. And sometimes it is earnings momentum, and sometimes it's earnings surprises. Sometimes it's price-to-sales cash flow, and then we put together our stock selection models.

All I'm trying to do is manage money and take care of my shareholders.

If you are a short-term trader, you have the right to come and go from our funds.

I sell these intermediate bond portfolios for people that can't go to stocks.

I still love the semiconductor industry.